Project Grant R01HL172942
Award Date
4/1/25
Completion Date
1/31/29
Dollars Obligated
$552K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop novel RNA-based gene therapeutics to improve the standard of care for a range of blood and vascular diseases. The $546,000 award to Thomas Jefferson University, doing business as Sidney Kimmel Medical College, will support research to: 1) select and characterize siRNA-based antithrombotic treatments with improved hemostatic...
This $227,250 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop an innovative "nanoproten" technology to mitigate the risk of vascular thromboses associated with prothrombotic autoantibodies. The research project at Saint Louis University has two key objectives: 1) investigating the biochemical characteristics and anticoagulant potential of the nanoproten molecule, and 2)...
This federal Project Grant award of $786,188 from the National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a novel, targeted gene therapy approach to prevent the failure of prosthetic bypass grafts used to treat arterial blockages in the lower extremities.
The primary objectives are to optimize a biodegradable hydrogel system that can effectively deliver small interfering RNA (siRNA) to downregulate key genes...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $626,956 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Thomas Jefferson University, doing business as Sidney Kimmel Medical College, to conduct research on the role of tRNA- and rRNA-derived small non-coding RNAs in acute lung injury (ALI). The study aims to characterize the dysregulation of these "hidden" small non-coding RNAs, particularly tRNA halves and rRNA fragments, in...
This $299,790 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of novel allosteric modulators of the thrombin receptor, protease-activated receptor 1 (PAR1), called Parmodulins, for the treatment of sickle cell disease (SCD).
The project aims to identify optimized Parmodulins with improved potency and oral activity, and confirm their efficacy in mouse models of SCD,...
This Project Grant award, valued at $125,658, was issued by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award will support research to unravel the mechanisms by which dietary saturated fatty acids (SFAs) influence platelet function and thrombosis in obesity.
The key objectives are to: 1) Determine how fatty acid uptake affects platelet membrane composition, 2) Assess the impact of dietary SFAs on platelet...
This Project Grant award of $767,077 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to validate and extend a platform technology for the delivery of protein-based drugs, with a focus on thrombolytic agents. The research aims to address key technical issues, including accommodating various thrombolytic proteins, enhancing multi-drug synergism, improving deep tissue penetration, and optimizing...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $407,975 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Arizona State University's Division, doing business as Orspa, to develop a lesion-targeted nanotherapeutic that utilizes CARMN transcripts as a pharmaceutical agent for the treatment of vascular smooth muscle cell (VSMC) dysfunction and neointimal hyperplasia (NIH). The project aims to optimize the CARMN-loaded platelet membrane-cloaked nanoparticles...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to develop novel lipid nanoparticle-based therapies for treating cardiac contractile disorders. The $793,828 award will fund experiments to characterize the efficacy and safety of different inhibitory nucleic acid cargos delivered via cardiotropic lipid nanoparticles (CLNPs) in healthy animal models and human myocardial tissue....
This $429,000 project grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research to characterize the biogenesis, regulation, and functions of short cyclic phosphate-containing RNAs (CP-RNAs) in cells and tissues. The research team at Thomas Jefferson University will use a newly developed CP-RNA-seq technology to perform a genome-wide expression analysis of CP-RNAs, which are largely...